Financial Performance - The company's revenue for the three months ended March 31, 2022, was HKD 26,197,000, a significant increase from HKD 12,918,000 in the same period last year, representing a growth of 102.4%[3] - For the nine months ended March 31, 2022, the total revenue was HKD 37,927,000, down from HKD 68,118,000 in the previous year, indicating a decline of 44.4%[3] - The gross profit for the three months ended March 31, 2022, was HKD 1,361,000, compared to HKD 3,649,000 in the same period last year, reflecting a decrease of 62.7%[3] - The operating loss for the nine months ended March 31, 2022, was HKD 12,367,000, an improvement from a loss of HKD 17,275,000 in the previous year, showing a reduction of 28.0%[3] - The company reported a net loss of HKD 9,869,000 for the three months ended March 31, 2022, compared to a net loss of HKD 17,623,000 in the same period last year, which is a 44.0% improvement[3] - The company’s basic loss per share for the three months ended March 31, 2022, was HKD 0.22, compared to HKD 0.40 in the same period last year, indicating a decrease of 45.0%[5] - The total comprehensive loss attributable to equity holders of the company for the nine months ended March 31, 2022, was HKD 23,051,000, compared to HKD 31,872,000 in the previous year, showing a reduction of 27.7%[5] - For the nine months ended March 31, 2022, the company reported a loss attributable to equity holders of HKD 23,413,000, compared to a loss of HKD 31,383,000 for the same period in 2021, representing a 25.4% improvement[16] - The basic and diluted loss per share for the nine months ended March 31, 2022, was HKD 5.22, compared to HKD 7.31 for the same period in 2021, indicating a decrease of 28.5%[16] - The net loss attributable to equity holders for 2022 was HKD 23,400,000, a 25% reduction from HKD 31,400,000 in 2021[24] Revenue Sources - The revenue from "Internet+" services (supply chain) for the three months ended March 31, 2022, was HKD 22,597,000, a substantial increase from HKD 4,358,000 in the same period last year, representing a growth of 419.5%[10] - The revenue from personal protective equipment manufacturing and distribution for the nine months ended March 31, 2022, was HKD 7,698,000, down from HKD 38,516,000 in the previous year, indicating a decline of 80.0%[10] - The personal protective equipment business continued to support revenue during the fifth wave of the COVID-19 pandemic in Hong Kong[25] Costs and Expenses - Total service costs for the three months ended March 31, 2022, were HKD 21,220,000, a significant increase from HKD 330,000 in the same period last year[16] - The cost of goods sold for the nine months ended March 31, 2022, was HKD 6,537,000, down from HKD 43,303,000 in the previous year, reflecting a decrease of 84.9%[16] - Sales and distribution expenses, along with administrative and operating expenses, amounted to HKD 34,700,000, a decrease of 24% from HKD 45,400,000 in 2021[24] Shareholder Information - The company has a total of 705,040,364 shares held by major shareholders, representing approximately 15.54% of the issued shares[37] - Integrated Asset Management (Asia) Limited holds 542,363,000 shares, accounting for 11.95% of the total[37] - Major shareholders include Guoyao Pharmaceutical Overseas Holdings Limited, which holds 650,000,000 shares, representing 14.32%[37] - The company has a total of 697,364,364 shares owned by a major shareholder, with 99.89% held by Ms. Zhang and Mr. Chen[41] Convertible Bonds and Stock Options - The company issued convertible bonds with a total value of HKD 89,625,000, which can be converted into a maximum of 249,651,810 shares at a conversion price of HKD 0.359 per share[41] - The conversion price of the convertible bonds was revised to HKD 0.221 per share, allowing for a maximum conversion into 405,542,986 shares[42] - The company plans to negotiate with bondholders regarding the renewal or further extension of the convertible bonds[43] - The stock option plan adopted on January 31, 2013, allows the board to grant options to eligible participants for a period of ten years[45] - The company has issued 4,000,000 stock options to a major shareholder as part of its stock option plan[41] - The total number of options granted under the old share option plan as of March 31, 2022, was 179,750,000, with 600,000 options expired[48] - Under the new share option plan, a total of 77,000,000 options were granted as of March 31, 2022[51] - The exercise price for the options granted was set at HKD 0.25 and HKD 0.33 for different plans[51] - The total number of options available for employees under the old plan was 66,550,000[48] Corporate Governance - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules Appendix 15, with some deviations noted[56] - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited results for the nine months ended March 31, 2022, and confirmed compliance with applicable accounting standards[60] - The roles of the chairman and CEO are held by the same individual, which the board believes is beneficial for the company's business prospects and management[56] - The company has established a code of conduct for securities trading by directors, confirming compliance with the required standards during the nine months ended March 31, 2022[59] - Non-executive and independent non-executive directors do not have a fixed term but must retire and seek re-election at least every three years[57] - The company has no interests in any business that directly or indirectly competes with its operations as of March 31, 2022[54] - The audit committee is responsible for reviewing the company's annual reports, interim reports, and quarterly reports, providing recommendations to the board[60] - The board will review the need to appoint a suitable individual as CEO if necessary, given the current dual role of the chairman and CEO[56] - The company is committed to regularly reviewing and updating its corporate governance practices to comply with GEM Listing Rules[57] Other Information - The company did not recognize any taxable profits during the period, resulting in no provision for Hong Kong profits tax[13] - The company reported a net foreign exchange gain of HKD 7,000 for the nine months ended March 31, 2022, compared to a gain of HKD 13,000 in the previous year[16] - The total equity attributable to equity holders as of March 31, 2022, was HKD (129,663,000), compared to HKD (140,556,000) as of March 31, 2021, indicating an improvement of 7.8%[19] - The company recognized share-based payment expenses of HKD 3,917,000 for the nine months ended March 31, 2022, compared to HKD 3,716,000 in the previous year, reflecting a slight increase of 5.4%[19] - The company’s total reserves as of March 31, 2022, were HKD 1,484,000, compared to HKD 1,484,000 as of March 31, 2021, remaining unchanged[19] - No dividend was recommended for the nine months ending March 31, 2022[29] - The group signed a cooperation agreement with a company in Zhejiang Province in March 2022 for the procurement of innovative anti-counterfeiting products[25] - The innovative anti-counterfeiting products incorporate patented technology and aim to enhance brand protection and corporate social responsibility[27] - The group plans to explore applications of innovative anti-counterfeiting products in the digital collectibles market[28] - The group was included in a 24-month standing agreement with the Hong Kong SAR Government's Logistics Services Department in March 2022[27] - The company has not reported any new product or technology developments in the provided content[49] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending March 31, 2022[53]
国药科技股份(08156) - 2022 Q3 - 季度财报